Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
<h4>Background</h4>Many patient organisations collaborate with drug companies, resulting in concerns about commercial agendas influencing patient advocacy. We contribute to an international body of knowledge on patient organisation-industry relations by considering payments reported in t...
Main Authors: | Shai Mulinari, Andreas Vilhelmsson, Emily Rickard, Piotr Ozieranski |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0235021 |
Similar Items
-
Drug company payments to General Practices in England: Cross-sectional and social network analysis.
by: Eszter Saghy, et al.
Published: (2021-01-01) -
Drug company payments to General Practices in England: Cross-sectional and social network analysis
by: Eszter Saghy, et al.
Published: (2021-01-01) -
Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
by: Shai Mulinari, et al.
Published: (2022-01-01) -
International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
by: Piotr Ozieranski, et al.
Published: (2023-03-01) -
Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.
by: Piotr Ozieranski, et al.
Published: (2023-01-01)